Table 3 Characteristics of female nAMD patients and female control subjects

Number of cases

30

20

13

7

–

–

Age (years)

75.7 ± 8.0

77.6 ± 9.1

75.6 ± 10.6

81.3 ± 3.6

0.459

0.099

nAMD type (typical:PCV:RAP)

–

12:4:4

7:4:2

5:0:2

–

0.501

Smoking (n, %)

1, 3.33

2, 0.10

1, 7.7

1, 14.3

0.391

0.639

HT (n, %)

15, 50.0

8, 20.0

7, 53.8

1, 14.3

0.497

0.013

DM (n, %)

4, 13.3

2, 10.0

2, 15.4

0, 0.0

0.723

0.274

d-ROMs (U. Carr)

407.0 ± 85.9

420.9 ± 76.1

406.5 ± 62.3

447.6 ± 96.3

0.552

0.336

BAP (μM/L)

2120.0 ± 204.7

2031.2 ± 243.9

2026.2 ± 225.9

2040.4 ± 293.4

0.187

0.913

SAF (AU)

2.1 ± 0.3

2.3 ± 0.6

2.3 ± 0.5

2.4 ± 0.7

0.076

0.742

Initial anti-VEGF drug (IVR:IVA)

–

11: 9

9: 4

2: 5

–

0.081

Cases that switched drug (n, %)

–

8, 40.0

6, 46.2

2, 28.6

–

0.444

Number of IVIs (one year)

–

5.8 ± 1.8

4.9 ± 1.8

7.3 ± 0.5

–

 < 0.001

VA (logMAR)

 Pre-teatment

–

0.52 ± 0.45

0.49 ± 0.52

0.57 ± 0.37

–

0.683

 One month later

–

0.43 ± 0.41

0.41 ± 0.49

0.49 ± 0.28

–

0.662

 One year later

–

0.45 ± 0.54

0.43 ± 0.62

0.50 ± 0.42

–

0.771

CMT (μm)

 Pre-treatment

–

370.4 ± 166.8

377.8 ± 188.4

356.7 ± 146.2

–

0.786

 One month later

–

250.3 ± 95.9

228.2 ± 79.1

291.3 ± 122.9

–

0.251

 One year later

–

253.0 ± 97.4

241.3 ± 60.9

274.6 ± 153.0

–

0.598